Daniel C Cho
Overview
Explore the profile of Daniel C Cho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1454
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Munster P, Iannotti N, Cho D, Kirkwood J, Villaruz L, Gibney G, et al.
Cancer Res Commun
. 2024 Mar;
4(3):785.
PMID: 38477691
No abstract available.
2.
Munster P, Iannotti N, Cho D, Kirkwood J, Villaruz L, Gibney G, et al.
Cancer Res Commun
. 2023 Dec;
3(12):2572-2584.
PMID: 38115208
Purpose: This phase Ib open-label, multicenter, platform study (NCT02646748) explored safety, tolerability, and preliminary activity of itacitinib (Janus kinase 1 inhibitor) or parsaclisib (phosphatidylinositol 3-kinase δ inhibitor) in combination with...
3.
Subbiah V, Kreitman R, Wainberg Z, Gazzah A, Lassen U, Stein A, et al.
Nat Med
. 2023 Apr;
29(5):1103-1112.
PMID: 37059834
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor)...
4.
Postel-Vinay S, Lam V, Ros W, Bauer T, Hansen A, Cho D, et al.
J Immunother Cancer
. 2023 Mar;
11(3).
PMID: 36927527
Background: The phase I first-in-human study ENGAGE-1 evaluated the humanized IgG1 OX40 agonistic monoclonal antibody GSK3174998 alone (Part 1 (P1)) or in combination with pembrolizumab (Part 2 (P2)) in patients...
5.
Davis E, Martin-Liberal J, Kristeleit R, Cho D, Blagden S, Berthold D, et al.
J Immunother Cancer
. 2022 Oct;
10(10).
PMID: 36316061
Background: OX40 is a costimulatory receptor upregulated on antigen-activated T cells and constitutively expressed on regulatory T cells (Tregs). INCAGN01949, a fully human immunoglobulin G1κ anti-OX40 agonist monoclonal antibody, was...
6.
Sanborn R, Pishvaian M, Callahan M, Weise A, Sikic B, Rahma O, et al.
J Immunother Cancer
. 2022 Aug;
10(8).
PMID: 35940825
Background: Phase 1/2 dose-escalation and expansion study evaluating varlilumab, a fully human agonist anti-CD27 mAb, with nivolumab in anti-PD-1/L1 naïve, refractory solid tumors. Methods: Phase 1 evaluated the safety of...
7.
Siefker-Radtke A, Cho D, Diab A, Sznol M, Bilen M, Balar A, et al.
Eur Urol
. 2022 Jun;
82(4):365-373.
PMID: 35643589
Background: Despite recent changes in the treatment landscape, there remains an unmet need for effective, tolerable, chemotherapy-free treatments for patients with advanced/metastatic urothelial carcinoma (mUC), especially cisplatin-ineligible patients. Objective: To...
8.
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
Tannir N, Cho D, Diab A, Sznol M, Bilen M, Balar A, et al.
J Immunother Cancer
. 2022 Apr;
10(4).
PMID: 35444058
Background: Immune checkpoint inhibitor-based combinations have expanded the treatment options for patients with renal cell carcinoma (RCC); however, tolerability remains challenging. The aim of this study was to evaluate the...
9.
Wen P, Stein A, van den Bent M, De Greve J, Wick A, de Vos F, et al.
Lancet Oncol
. 2021 Nov;
23(1):53-64.
PMID: 34838156
Background: Effective treatments are needed to improve outcomes for high-grade glioma and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated in adult patients with recurrent or...
10.
Emamekhoo H, Olsen M, Carthon B, Drakaki A, Percent I, Molina A, et al.
Cancer
. 2021 Nov;
128(5):966-974.
PMID: 34784056
Background: Nivolumab plus ipilimumab (NIVO + IPI) has demonstrated long-term efficacy and safety in patients with previously untreated, advanced renal cell carcinoma (aRCC). Although most phase 3 clinical trials exclude...